{
    "clinical_study": {
        "@rank": "11492", 
        "acronym": "RADIANT", 
        "arm_group": [
            {
                "arm_group_label": "Dose A", 
                "arm_group_type": "Active Comparator", 
                "description": "Dose A:  Botulinum toxin type A"
            }, 
            {
                "arm_group_label": "Dose B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dose B:  Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of botulinum toxin type A compared to\n      placebo control for the treatment of moderate to severe crow's feet lines."
        }, 
        "brief_title": "Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Skin Aging", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Moderate to severe crow's feet lines\n\n          -  Female or male, 18 to 65 years of age and in good general health\n\n          -  Women of childbearing potential (WOCBP) must agree to use an effective method of\n             birth control during the course of the study\n\n        Exclusion Criteria:\n\n          -  Any neurological condition that may place the subject at increased risk with exposure\n             to botulinum toxin type A\n\n          -  Muscle weakness or paralysis, particularly in the area receiving study treatment\n\n          -  Active skin disease or irritation at the treatment area\n\n          -  Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated\n             by manually spreading the skin apart\n\n          -  Treatment with botulinum toxin type A for crow's feet lines in the last 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "247", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776606", 
            "org_study_id": "RT001-CL019"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose A", 
                "description": "Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines", 
                "intervention_name": "Botulinum Toxin Type A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose B", 
                "description": "Placebo, Dose B; dose applied to the lateral canthal lines", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Coral Gables", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33146"
                }, 
                "name": "Dermatology Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines", 
            "safety_issue": "No", 
            "time_frame": "Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with 2 point or greater improvement from baseline using the Investigator Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Proportion of subjects with 1 point or greater improvement from baseline using the Investigator Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Proportion of subjects with a 2 point or greater improvement from baseline using the Patient Severity Assessment", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "source": "Revance Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Revance Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}